Slide 1: Safe harbor
Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statemen
Slide 2: Schedule of events
Schedule of events 3 Introduction to the company and platform overview Clinical data & conclusions Q&A
Slide 3: Mission statement
mission statement 4 Replimune aims to transform the lives of cancer patients through the development of highly effective but low toxicity therapies that provide durable benefit across a broad range of tumor types
Slide 4: Founded by former BioVex management team that developed T-VEC
5 Founded by the former BioVex management team that developed T-VEC Proprietary ‘Immulytic’ oncolytic immuno-gene therapy platform Intended to maximally activate the immune system against a patient’s cancer Establish Replimune’s products as the second cornerstone of immuno-oncology RP1 – in multiple
Slide 5: Summary of data and conclusions to be presented
Summary of data & conclusions to be presented 6 RP1 alone & combined with nivolumab is well tolerated MOA of RP1 alone & in combination with nivolumab was confirmed Strong support was provided for Replimune’s programs in melanoma & CSCC Includes two of the three anti-PD1 refractory cutaneous melanom
Slide 6: Oncolytic immuno-gene therapy
Oncolytic immuno-gene therapy 7 The use of viruses that selectively replicate in & kill tumors to treat cancer Directly kills tumors Highly inflammatory Activates both innate and adaptive immunity Releases the full array of tumor antigens into an inflamed environment Systemically activates the immun
Slide 7: Replimune's therapies are designed to be best in class
Replimune’s therapies are designed to be best in class 8 Designed to maximize local tumor destruction Clinically beneficial in its own right Provides abundant release of tumor antigens to provide the systemic vaccination effect Designed to maximize the immunogenicity of cell death Increases the pote
Slide 8: Most patients don't respond to immune checkpoint blockade
Most patients don’t respond to immune checkpoint blockade 9 ORR for tumor types where immune checkpoint inhibitors are FDA approved Source: re-drawn from FDA presentation at AAADV Workshop, 5/8/2019. Data as of 11/2018.
Slide 9: Intended to become the fourth cornerstone of cancer treatment
Intended to become the fourth cornerstone of cancer treatment ( Immune activation: Currently missing from Overcome defenses to the host immune response - dominated the cancer paradigm treatment Oncolytic immuno gene therapy by anti-PDl Immuno therapy Surgery/RT Chemo therapy Targeted therapies Tr
Slide 10: A pipeline designed to address specific needs in cancer therapy: Need 1
A pipeline designed to address specific needs in cancer therapy 11 RP1 Need 1: Improve outcomes in immune sensitive cancers Tumors that already have a level of responsiveness to anti-PD1 blockade In all cases there still remains a substantial unmet need Intend to establish a franchise for the treatm
Slide 11: A pipeline designed to address specific needs in cancer therapy: Need 2
A pipeline designed to address specific needs in cancer therapy 12 Need 2: Extend utility of immunotherapy in more immune resistant cancers RP2 RP3 Tumors where anti-PD1 therapy is less effective, e.g. head & neck cancer, TNBC Tumor types where anti-PD1 is not effective, e.g. colorectal cancer Targe
Slide 12: Replimune's Immulytic platform
Replimune’s Immulytic platform 13 1. A potent underlying HSV-1 strain anti-CTLA-4 CTLA-4, CD40L & RP1 RP2 RP3 cold tumors There is great diversity among clinical HSV strains 2. Increased tumor killing & spread Armed with GM-CSF & a potent fusogenic protein (GALV-GP R-) 3. Delivery of potent immune s
Slide 13: Robust and steadily advancing pipeline
Replimune has a robust & steadily advancing pipeline 14 Expresses GALV-GP R-& GM-CSF Phase 2 underway in 4 tumor types + nivolumab Melanoma + nivolumab Enrolling Non-melanoma skin cancers + nivolumab Enrolling Bladder cancer + nivolumab Enrolling MSI high cancer + nivolumab Enrolling RP1+cemiplimab
Slide 14: Phase 1/2 clinical trial of RP1 alone and with nivolumab
15 Phase 1/2 clinical trial of RP1 alone & in combination with nivolumab
Slide 15: Key objectives of the RP1 Phase 1 trial
Key objectives of the RP1 Phase 1 part of the clinical trial 16 Demonstrate safety of RP1, alone & combined with nivolumab Via both superficial and deep injection routes Determine the recommended dose of RP1 for further development alone & combined with nivolumab Confirm the MOA of RP1 alone & in co
Slide 16: Clinical trial design
Clinical trial design 17 First in human two stage trial of RP1 alone and in combination with nivolumab Phase 1 part 1: Dose escalation of RP1 alone given up to 5 injections into a single tumor in three dose level cohorts each by either direct or imaging guided injection Dose level 1: 1x104 pfu/ml, 1
Slide 17: Key inclusion criteria
Phase 1 key inclusion criteria (dose rising & combined with nivolumab) 18 Key inclusion criteria Advanced or metastatic non-neurological solid tumors, which have progressed on standard therapy or cannot tolerate standard therapy, or for which there is no standard therapy preferred to enrollment in a
Slide 18: Primary and secondary objectives
Phase 1 primary & secondary objectives (dose rising & combined with nivolumab) 19 Primary objectives To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose of RP1 To assess the safety and tolerability of RP1 alone and in combination with nivolumab Secondary objectives To a
Slide 19: Phase 1 data summary
Phase 1 data summary 20 The side effect profile was as expected alone & in combination Dose rising monotherapy phase The recommended dose for further development was established Tumor destruction was demonstrated, including delayed systemic tumor reductions without further therapy Kinetics of detect
Slide 20: Phase 1 data summary
Phase 1 data summary EL = The side effect profile was as expected alone & in combination * Dose rising monotherapy phase The recommended dose for further development was established Tumor destruction was demonstrated, including delayed systemic tumor reductions without further therapy » Kinetics of
Slide 21: Patients enrolled - dose escalation
Patients enrolled - dose escalation 22 * The inclusion criteria were narrowed to exclude PS2 soon after the trial start Total Melanoma Colorectal Head and neck Breast Esophage al Pancreatic CSCC Cholangiocarcin oma Number 22 8 5 2 2 2 1 1 1 Age: Range 22-81 22-71 30-59 61-78 55-65 66-81 58 58 68 ECO
Slide 22: Patients enrolled - in combination with nivolumab
Patients enrolled - in combination with nivolumab 23 Total Cutaneous melanoma Uveal melanoma Mucosal melanoma CRC CSCC BCC Breast Bladder Adeno. of cecum MSI-H (Colon) Esepha geal Number 14 3 2 1 1 1 1 1 1 1 1 1 Age: Range 28-74 28-67 53-64 74 70 61 56 59 51 41 50 70 ECOG performance status: 0, 1 (#
Slide 23: Patients enrolled - current focus for registration directed development
Patients enrolled - in combination with nivolumab 24 Current focus for registration directed clinical development Total Cutaneous melanoma Uveal melanoma Mucosal melanoma CRC CSCC BCC Breast Bladder Adeno. of cecum MSI-H (Colon) Esepha geal Number 14 3 2 1 1 1 1 1 1 1 1 1 Age: Range 28-74 28-67 53-6
Slide 24: Advanced patients were enrolled
Advanced patients were enrolled 25 4401-1003 4401-1006 4401-1007 4401-1016 4402-1006 4401-1019 4401-1020 4401-1018 4401-1005 4401-1008
Slide 25: Advanced patients were enrolled
Advanced patients were enrolled 4401-1019 4401-1020 4401-1018 4401-1005 4401-1008
Slide 26: Treatment-related adverse events – dose escalation
Treatment-related adverse events – dose escalation 27 Side effects as expected for an oncolytic immunotherapy ‘Flu-like constitutional symptoms, chills & rigors were the main side effects observed; self resolving within 72hrs of injection No obvious differences between deep & superficial dosing Mode
Slide 27: Treatment-related adverse events – with nivolumab
Treatment-related adverse events – with nivolumab 28 No evidence of increased side effects as compared to that expected for either drug alone Two procedure-related AEs were seen (pneumothorax, n=2, self resolved) 10 SAEs seen, 0 related to RP1 or nivolumab Procedure-related SAE: Pneumothorax PD-rela
Slide 28: Injection site erythema
Injection site erythema (24-48hrs post injection) 29 4401-1002 Melanoma 4401-1011 Colorectal cancer 4401-1013 Breast cancer 4402-1001 CSCC
Slide 29: Safety and tolerability conclusions
Safety & tolerability conclusions 30 RP1 is well tolerated alone and in combination with nivolumab, with side effects as expected for each agent alone Both direct injection of superficial & nodal tumors, & imaging guided injection of deep/visceral tumors were well tolerated and practical The recomme
Slide 30: RP1 replication and seroconversion
31 RP1 replication & seroconversion
Slide 31: Detection of RP1 in swab and blood samples
Detection of RP1 in swab & blood samples: Dose Escalation Blood Deep cohort Blood: Deep Blood Superfical cohorts Blood: Superficial 32 C44o0h1o-1rt0:013b 1B 4402-1006 109 109 4401-1008 Cohort: 2a 4401-1013 2 A * C44o0h1o-1rt0:129b 4401-1020 C44o0h1o-1rt0:231b 2B 4401-1011 108 3 A108 Cohort: 3a 4402-
Slide 32: Detection of RP1 in swab and blood samples
Detection of RP1 in swab & blood samples: Dose Escalation Blood Deep cohort Blood: Deep Blood Superfical cohorts Blood: Superficial 33 C44o0h1o-1rt0:013b 1B 4402-1006 109 109 4401-1008 Cohort: 2a 4401-1013 2 A * C44o0h1o-1rt0:129b 4401-1020 C44o0h1o-1rt0:231b 2B 4401-1011 108 3 A108 Cohort: 3a 4402-
Slide 33: RP1 detection and seroconversion conclusions
RP1 detection & seroconversion conclusions 34 RP1 was detected in the blood and on the injected tumor surface for up to two weeks (time of next dose) in some patients These kinetics are suggestive of robust virus replication* All HSV seronegative patients seroconverted by the third RP1 dose, and ant
Slide 34: RP1 detection and seroconversion conclusions
RP1 detection & seroconversion conclusions Ee = RP1 was detected in the blood and on the injected tumor surface for up to two weeks (time of next dose) in some patients = These kinetics are suggestive of robust virus replication* = All HSV seronegative patients seroconverted by the third RP1 dose, a
Slide 35: Biomarkers
Biomarkers 36 Tumor biopsies were taken at baseline & day 43 in the expansion cohort Assessed for the presence of tumor Stained for PD-L1 and CD8 T cells Subjected to Nanostring analysis Inflammatory gene signature Bespoke oncolytic virus specific panel of genes Blood samples were assessed for the g
Slide 36: PD-L1 and CD8 T cell staining and pathology summary
PD-L1 & CD8 T cell staining & pathology summary 37 Most post baseline biopsies showed extensive necrosis and/or were tumor free (see Appendix for summary table) Increases in both PD-L1 and CD8 T cells were seen across tumor types (see Appendix for summary table) Lack of tumor and/or necrosis in 50%
Slide 37: CD8 T cell and PD-L1 staining is increased across tumor types
CD8 T cell & PD-L1 staining is increased across tumor types 38 4401-1024 Esophageal cancer PD-L1 4403-1002 CSCC PD-L1 CD8 CD8 Baseline D43
Slide 38: CD8 T cell and PD-L1 staining is increased across tumor types
CD8 T cell & PD-L1 staining is increased across tumor types 39 1105-1001 Mucosal melanoma (Ipilimumab/nivolumab refractory) 1119-1002 MSI-H CRC PD-L1 PD-L1 CD8 CD8 Baseline D43
Slide 39: Reversal of T cell exclusion with RP1 combined with nivolumab
Reversal of T cell exclusion with RP 1 combined with nivolumab .. .' ·'•. ;;. " .. CDS Baseline CDS D43 <!}-Replimune 4403-1003 Cutaneous melanoma (ipilimumab/nivolumab refractory) . ·,·
Slide 40: Reversal of T cell exclusion with RP1 combined with nivolumab
..Reversal PD-L 1 Baseline ofT cell exclusion with RPl combined with nivolumab PD-L 1 D43 <!}-Replimune 4403-1003 Cutaneous melanoma (ipilimumab/nivolumab refractory)
Slide 41: Nanostring analysis shows increased immune activation
Nanostring analysis shows increased immune activation 42 * 0.0229 9 1105-1C0X01C-LM-9ucosal melanoma1105-100C1D-M27ucosal melanoma1105-10C0X1C-MRu6cosal melanoma1105-10C0D12-M76ucosal melanoma1105-1001-Mucos CCL-5 0 2.0 2 4 0 ancer4401-1024-Esophageal cancer4401-1024-Esophageal cancer4401-1024-Esoph
Slide 42: RP1+nivolumab increases autoimmune B cell responses
RP1+nivolumab increases autoimmune B cell responses 43 Oncimmune have developed a high throughput approach to detecting autoimmune B cell responses which may be useful biomarkers for immuno-oncology Oncimmune used this platform to assess pre-and post-blood samples (29 days) from 4 RP1+nivolumab trea
Slide 43: RP1 combined with nivolumab induces vitiligo
RP1 combined with nivolumab induces vitiligo (Phase 2 patient) 44 Baseline D57 D113 Left foot Vitiligo D113 Right heel (injected once with RP1; subsequent injections into inguinal nodes) Left chest 1119-2001 Cutaneous melanoma
Slide 44: Biomarker conclusions
Biomarker conclusions 45 Increases in CD8 T cells & PD-L1 were seen across tumor types Reversal of T cell exclusion was observed Most biopsies showed extensive necrosis and/or were tumor free Increases in autoimmune B cell responses were seen, suggestive of activation broad immune Nanostring data de
Slide 45: Biomarker conclusions
Biomarker conclusions a = Increases in CD8 T cells & PD-L1 were seen across tumor types = Reversal of T cell exclusion was observed = Most biopsies showed extensive necrosis and/or were tumor free = Increases in autoimmune B cell responses were seen, suggestive of broad immune activation = Nanostrin
Slide 46: Anti-tumor activity - dose rising cohorts
Anti-tumor activity - dose rising cohorts (single agent RP1) 47 CT scans per protocol were performed at baseline and at 30 days post the last RP1 dose for the dose rising cohort patients treated with single agent RP1 Tumor shrinkage was seen in injected and uninjected tumors, including in the three
Slide 47: Tumor necrosis in visible tumors in dose rising cohorts
Tumor necrosis in the visible tumors in the dose rising cohorts 48 4402-1004 Salivary gland cancer 4401-1008 Breast cancer 4401-1001 Melanoma The only other cutaneous tumor in the Only two patients in the dose rising cohorts had a superficially visible (i.e. cutaneous) tumor which was injected dose
Slide 48: Shrinkage of injected tumors
Shrinkage of injected tumors 49 Baseline 30 day follow up 4402-1001 CSCC Central necrosis of a large injected tumor in the neck. The patient also had lung metastases 4401-1005 Colorectal cancer Destruction of the injected tumor nodule. The patient also had extensive additional abdominal disease 4401
Slide 49: Delayed systemic anti-tumor effects in dose rising cohort
Delayed systemic anti-tumor effects in the dose rising cohort 50 Patients were followed per protocol in the dose rising for 30 days post the last RP1 dose to collect safety data, followed by a CT scan Delayed, post study (CT scans not available), anti-tumor effects (systemic reduction in disease bur
Slide 50: Anti-tumor activity – combination with nivolumab
Anti-tumor activity – combination with nivolumab 51 Two of the three patients enrolled with cutaneous melanoma, all of whom were ipilimumab & pembrolizumab or ipilimumab/nivolumab refractory, are responding The first ipilimumab/nivolumab patient in Phase 2 with follow up scans has also responded (se
Slide 51: Patient 4403-1002 (chemotherapy refractory CSCC)
Patient #: 4403-1002 (chemotherapy refractory CSCC) 52 3rd Jan 2019 7th October 2019 13th May 2019 3rd Jan 2019 21st Jan 2019 19th August 2019 Patient with extensive recurrent CSCC previously treated with surgery (including skin grafts), radiotherapy, cisplatin/5FU, then electrochemotherapy Now CR w
Slide 52: Patient 4401-1022 (refractory melanoma)
Patient #: 4401-1022 (ipilimumab/pembrolizumab refractory melanoma) 53 Disease sites: Breast, lung, mediastinal and peritoneal anterior to the spleen RP1 injection site: Lesion behind the left ear Confirmed progression on prior immune checkpoint blockade, where two sequential PET scans demonstrated
Slide 53: Patient 4403-1003 (refractory melanoma)
Patient #: 4403-1003 (ipilimumab/nivolumab refractory melanoma) 54 10th June 2019 24th June 2019 (pre nivolumab) 2nd September 2019 Patient history: Metastatic disease initially treated with ipili/nivo with best response of SD, then clear progression in the groin & thigh when radiotherapy followed b
Slide 54: Patient 4403-1003 (refractory melanoma)
Patient #: 4403-1003 (ipilimumab/nivolumab refractory melanoma) 55 Patient also had nodes in the groin which increased and are now reducing and lung metastases which following no change for prior 18 months are now reducing Patient quality of life has also greatly improved, from being essentially imm
Slide 55: Patient 1119-2003 (refractory melanoma)
Patient #: 1119-2003 (ipilimumab/nivolumab refractory melanoma) 56 26th August 2019 2nd July 2019 (screening) 17th Sept 2019 1st July 2019 (screening) 24th October 2019 The first ipilimumab/nivolumab refractory melanoma patient enrolled into the Phase 2 part of the study. Other such patients do not
Slide 56: Patient 4403-1001 (refractory uveal melanoma)
Patient #: 4403-1001 (ipilimumab/nivolumab refractory uveal melanoma) 57 Baseline (2nd Jan 2019) 24th April 2019 Patient has numerous additional subcutaneous lesions - remains on nivolumab at >9 months
Slide 57: Patient 1119-1002 (MSI-H colorectal cancer)
Patient #: 1119-1002 (chemotherapy refractory MSI-H colorectal cancer) 58 Chemotherapy refractory MSI-H colorectal cancer 5cm liver metastasis and other liver metastases of around 1cm The liver lesions showed initial substantial increase (presumed inflammation), then reduction A biopsy taken at C4 d
Slide 58: Patient 4401-1024 (esophageal cancer)
Patient #: 4401-1024 (esophageal cancer) 59 Heavily pre-treated esophageal cancer (8 prior therapies) Lung lesions and lesions around the esophagus. Largest lung lesion injected 6 times after which too soft for further injections. Further smaller lung lesion injected once, but discomfort and self re
Slide 59: Tumor shrinkage after one RP1 dose (melanoma)
Tumor shrinkage after one RP1 dose (1105-2003; pembrolizumab refractory melanoma) 60 23rd October2019 (pre-nivolumab) 10th October 2019 16th October 2019 Increased drainage noted by D6 prior to tumors reducing by D13 (pre-nivolumab) Patient remains on treatment at 2-3 weeks
Slide 60: Tumor shrinkage after one RP1 dose (CSCC)
Tumor shrinkage after one RP1 dose (4402-2001; CSCC) 61 1st July 2019 (post one dose of RP1, no nivolumab) 16th July 2019 (post 2 doses of RP1 & 1 dose of nivolumab) 16th June 2019 (baseline) Patient with recurrent CSCC of the neck (bilateral), previously treated with cisplatin-based chemoradiation
Slide 61: Patient 4402-2001 (CSCC)
Patient #: 4402-2001 (CSCC) 62 Right neck (injected) 8 weeks Left neck (not injected) 8 weeks Baseline 16 weeks Baseline 16 weeks The protocol mandated biopsy of the injected tumor taken at day 43 was tumor free No tumor was found to remain when a biopsy was attempted from the left neck In addition
Slide 62: Patient 4402-2001 (CSCC)
Patient #: 4402-2001 (CSCC) 63 Baseline 16 weeks The patient also had baseline retroperitoneal tumors which have completely resolved The only remaining disease are a number of non-measurable bone metastases, which were the main source of the cancer pain which has now resolved: These are now scleroti
Slide 63: Anti-tumor activity conclusions
Anti-tumor activity conclusions 64 Activity was seen with both RP1 alone and in combination with nivolumab Including the rapid tumor reductions seen before the introduction of nivolumab In particular we saw clear clinical activity in CSCC and in anti-PD1 refractory melanoma Provides strong support f
Slide 64: Overall conclusions from the clinical data so far
Overall conclusions from the clinical data so far 65 RP1 is well tolerated alone & in combination with nivolumab Both direct injection & imaging guided injection were well tolerated and practical RP1 provides potent oncolytic activity & abscopal effects Clinical activity was seen for RP1 alone & in
Slide 65: Overall conclusions from the clinical data so far
Overall conclusions from the clinical data so far a = RP1 is well tolerated alone & in combination with nivolumab = Both direct injection & imaging guided injection were well tolerated and practical = RP1 provides potent oncolytic activity & abscopal effects = Clinical activity was seen for RP1 alon
Slide 66: Q&A
Q&A } Replimune
Slide 67: Administration site, volume and method for deep dose rising cohort
Administration site, volume & method used for each deep dose rising cohort patient 68 used (CT or Patient # Tumor type Injection site Volume/ injection (range in mL, given up to 5 times) Imaging guidance ultrasound) 4401-1003 Melanoma Lung 5.0-10.0 Ultrasound 4401-1006 Colorectal Liver 3.0 Ultrasoun
Slide 68: Administration site, volume and method for deep expansion cohort
Administration site, volume & method used for each deep expansion cohort patient 69 used (CT or Patient # Tumor type Injection site Volume/ injection (range in mL, given up to 8 times) Imaging guidance ultrasound) 1105-1002 Melanoma Liver 0.5-2.7 CT/Ultrasound 1110-1003 Colorectal Liver 3.1 CT 1110-
Slide 69: HSV antibody titres – dose rising cohorts
HSV antibody titres – dose rising cohorts 70 Superficial Deep HSV-1 Seronegative patients HSV-1 Seronegative patients HSV-1 Seropositive patients HSV-1 Seropositive patients
Slide 70: HSV antibody titres – expansion cohorts
HSV antibody titres – expansion cohorts 71 Deep Superficial HSV-1 Seronegative patients (no seronegative patients at baseline) HSV-1 Seronegative patients HSV-1 Seropositive patients HSV-1 Seropositive patients
Slide 71: Most biopsies showed extensive necrosis and/or were tumor free
Most biopsies showed extensive necrosis and/or were tumor free 72 SCC. July 2019: 2 biopsies from last palpable area tumor free (confirmed CR) rare pigmented foamy macrophages inflammation melanocytes, moderate to heavy chronic inflammation * After three doses of RP1 & two doses of nivolumab ** Verb
Slide 72: PD-L1 and CD8 T cell staining summary
PD-L1 & CD8 T cell staining summary 73 (two biopsies) IHC & assessment performed by DCL Pathology *After two doses of RP1 & one of nivolumab **Combined peritumoral (0-3+) & intra-tumoral (0-3+) CD8 staining intensity score. UNK = unknown (archival biopsy without tumor). Data from remaining patients
Slide 73: RP1 induces abscopal anti-tumor effects
RP1 induces abscopal anti-tumor effects 74 Multiple patients showed abscopal (i.e. uninjected) tumor reduction, including: Reductions at multiple tumor sites (hilar nodes, liver tumors, bone lesions, lymph nodes) following injection of RP1 into a either a single lung or a single liver tumor up to 5
Slide 74: Randomized controlled Phase 2 study in CSCC (CERPASS)
Randomized controlled Phase 2 study in CSCC (CERPASS) 75 RP1 IT Q3W x 8 doses† (1x106 PFU/mL for one dose followed by 1x107 PFU/mL for 7 doses) + Cemiplimab 350mg Q3W IV Key Eligibility Criteria: • • • • Locally-advanced/metastatic CSCC ECOG PS 0 or 1 No active autoimmune disease No prior treatment
Slide 75: Phase 1b clinical trial in solid organ transplant recipients with CSCC
Phase 1b clinical trial in solid organ transplant recipients with CSCC 76 Key Eligibility Criteria: • Locally-advanced/metastatic CSCC ECOG PS 0 or 1 Renal or hepatic organ allograft recipients on stable immunosuppressive regimen for >12 mos No prior systemic anti-cancer treatment for CSCC No transp
Slide 76: Replimune's key target milestones
Replimune’s key target milestones 77 RP1 Randomized 2 data in CSCC 2019 2020 2021 with RP2 +/-RP2 RP3 Initiated Phase 1 nivolumab H1 2020: Manufacturing facility operational 2021: RP2 Phase 2 data 2020: RP2 Phase 1 data 2020: Initiate clinical development of RP3 H2 2021: controlled Phase Q1 2020: In
Slide 77: Replimune's critical focus on manufacturing
Replimune’s critical focus on manufacturing 78 Product candidates currently manufactured by a CMO for ongoing clinical development For later stage development & commercialization, in-house manufacturing is preferable The team has extensive manufacturing experience 63,000 ft2 manufacturing facility l
Slide 78: Reception, offices and utilities
Reception,offices & utilities
Slide 79: Reception, offices and utilities
Reception, offices & utilities a i. me
Slide 80: Production areas
Production areas